GlassScriptPhysician profile
Camille Adeimy
NPI 1477785160
$1,701.39
in general payments reported to CMS, 2019-2025
17 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $483 · 2020: $849 · 2021: $286 · 2023: $83.60.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $65.83 · Education: $17.77.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $65.83 |
| Education | $17.77 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alexion Pharmaceuticals, INC. | $370.18 | 2020-2021 | |
| Astrazeneca Pharmaceuticals LP | $264.46 | 2019-2021 | |
| Novartis Pharmaceuticals Corporation | $220.47 | 2019-2020 | |
| Astellas Pharma US INC | $132.91 | 2019-2020 | |
| Pfizer INC. | $130.33 | 2019-2023 | |
| E.R. Squibb & Sons, L.L.C. | $125.93 | 2019 | |
| Glaxosmithkline, LLC. | $115.39 | 2020 | |
| Puma Biotechnology, INC. | $90.68 | 2020 | |
| Janssen Biotech, INC. | $72.98 | 2019 | |
| Merck Sharp & Dohme LLC | $69.68 | 2019-2020 | |
| Gilead Sciences, INC. | $29.85 | 2019-2021 | |
| Jazz Pharmaceuticals INC. | $24.57 | 2019 | |
| Karyopharm Therapeutics INC. | $24.33 | 2021 | |
| Incyte Corporation | $17.05 | 2019 | |
| Lilly USA, LLC | $12.58 | 2019 |
2 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Camille Adeimy listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.